22 May 2013
Keywords: Elan, Biogen Idec, Tysabri, FDA warnings, PML, Risk factors
Article | 08 February 2010
Irish drugmaker Elan saw its share price drop 5.8% to 5.05 euros, after it was revealed that the US Food and Drug ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.